Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone furoate/vilanterol in moderate COPD with cardiovascular risk
CTR20131495Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluticasone propionate + vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Sep 2014; status: completed.
02
Drugs
fluticasone propionate + vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20131495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131495.